Arcutis Biotherapeutics, Inc. (ARQT)Healthcare | Biotechnology | Westlake Village, United States | NasdaqGS
23.78 USD
-1.09
(-4.383%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 23.74 -0.04 (-0.040%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:07 a.m. EDT
The investment case here is driven by a powerful divergence between a deteriorating technical trend and a fundamentally recovering business. While the stock has suffered a brutal 43% decline over the last five years, the most recent annual performance tells a different story: a massive 92% surge in value and a 59% jump in revenue growth. This turnaround is priced in, yet the balance sheet remains pristine with a fortress-like current ratio of nearly 3x and manageable debt levels. The high forward P/E reflects the market's expectation of continued expansion as the dermatology platform compounds. Short-term, the setup looks attractive despite the weak statistical forecast. The price is hovering near its 200-day average, and the options chain reveals aggressive speculation on a breakout to the upside, with heavy call open interest at strikes well above the current level. This suggests smart money sees a catalyst approaching. However, the recent insider selling and the stock's failure to break above the 52-week high create some friction. I am leaning bullish for the near term based on the options flow and the reversal of the long-term downtrend, but the lack of a dividend and the inherent volatility of a biotech turnaround keep the short-term rating from being a full conviction buy. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.163814 |
| MSTL | 0.187633 |
| AutoARIMA | 0.191503 |
| AutoETS | 0.191574 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 3.18 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.003 |
| Excess Kurtosis | 0.39 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 51.744 |
| Revenue per Share | 3.598 |
| Market Cap | 2,988,954,880 |
| Trailing P/E | 113.24 |
| Forward P/E | 18.25 |
| Beta | 1.53 |
| Profit Margins | 6.15% |
| Website | https://www.arcutis.com |
As of Aug. 22, 2026, 5:07 a.m. EDT: Speculators are positioning for a significant upside breakout, evidenced by heavy open interest in out-of-the-money calls at strikes significantly above the current price (30 and 32.5 for August expiry; 30 and 35 for January expiry). Conversely, put activity is concentrated deep in-the-money at lower strikes (12.5 and 17.5), suggesting a floor rather than a bearish bet. The skew in volume and open interest strongly favors a bullish scenario over the next few months.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.62336814 |
| Address1 | 3,027 Townsgate Road |
| Address2 | Suite 300 |
| All Time High | 40.88 |
| All Time Low | 1.76 |
| Ask | 31.0 |
| Ask Size | 2 |
| Audit Risk | 2 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,769,560 |
| Average Daily Volume3 Month | 1,679,933 |
| Average Volume | 1,679,933 |
| Average Volume10Days | 1,769,560 |
| Beta | 1.526 |
| Bid | 23.75 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 1.756 |
| City | Westlake Village |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 23.78 |
| Current Ratio | 2.917 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 24.88 |
| Day Low | 23.74 |
| Debt To Equity | 51.744 |
| Display Name | Arcutis Biotherapeutics |
| Earnings Call Timestamp End | 1,785,961,800 |
| Earnings Call Timestamp Start | 1,785,961,800 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,131,200 |
| Earnings Timestamp Start | 1,793,131,200 |
| Ebitda | 36,503,000 |
| Ebitda Margins | 0.07867 |
| Enterprise To Ebitda | 78.474 |
| Enterprise To Revenue | 6.174 |
| Enterprise Value | 2,864,539,904 |
| Eps Current Year | 0.41167 |
| Eps Forward | 1.30333 |
| Eps Trailing Twelve Months | 0.21 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 26.7004 |
| Fifty Day Average Change | -2.9203987 |
| Fifty Day Average Change Percent | -0.109376594 |
| Fifty Two Week Change Percent | 62.336815 |
| Fifty Two Week High | 31.77 |
| Fifty Two Week High Change | -7.99 |
| Fifty Two Week High Change Percent | -0.25149512 |
| Fifty Two Week Low | 15.13 |
| Fifty Two Week Low Change | 8.650001 |
| Fifty Two Week Low Change Percent | 0.57171184 |
| Fifty Two Week Range | 15.13 - 31.77 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,580,481,000,000 |
| Float Shares | 93,801,397 |
| Forward Eps | 1.30333 |
| Forward P E | 18.245573 |
| Free Cashflow | 21,685,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 354 |
| Fullday Change | -1.09 |
| Fullday Change Percent | -4.38279 |
| Fullday Price | 23.74 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.91143 |
| Gross Profits | 422,884,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01779 |
| Held Percent Institutions | 1.08794 |
| Implied Shares Outstanding | 125,691,961 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. |
| Long Name | Arcutis Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,988,954,880 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_549019944 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 28,519,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,123,445,230 |
| Number Of Analyst Opinions | 8 |
| Open | 24.88 |
| Operating Cashflow | 39,309,000 |
| Operating Margins | 0.12651 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 805 418 5006 |
| Post Market Change | -0.040000916 |
| Post Market Change Percent | -0.16821243 |
| Post Market Price | 23.74 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 24.87 |
| Price Eps Current Year | 57.764717 |
| Price Hint | 2 |
| Price To Book | 13.542141 |
| Price To Sales Trailing12 Months | 6.441977 |
| Profit Margins | 0.06147 |
| Quick Ratio | 2.455 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -1.09 |
| Regular Market Change Percent | -4.38279 |
| Regular Market Day High | 24.88 |
| Regular Market Day Low | 23.74 |
| Regular Market Day Range | 23.74 - 24.88 |
| Regular Market Open | 24.88 |
| Regular Market Previous Close | 24.87 |
| Regular Market Price | 23.78 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,535,819 |
| Return On Assets | 0.05091 |
| Return On Equity | 0.15864 |
| Revenue Growth | 0.593 |
| Revenue Per Share | 3.598 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 125,691,961 |
| Shares Percent Shares Out | 0.1171 |
| Shares Short | 14,717,905 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 13,561,565 |
| Short Name | Arcutis Biotherapeutics, Inc. |
| Short Percent Of Float | 0.1249 |
| Short Ratio | 10.0 |
| Source Interval | 15 |
| State | CA |
| Symbol | ARQT |
| Target High Price | 40.0 |
| Target Low Price | 34.0 |
| Target Mean Price | 36.875 |
| Target Median Price | 37.0 |
| Total Cash | 238,552,000 |
| Total Cash Per Share | 1.898 |
| Total Debt | 114,137,000 |
| Total Revenue | 463,980,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.21 |
| Trailing P E | 113.238106 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.61625 |
| Two Hundred Day Average Change | -1.8362484 |
| Two Hundred Day Average Change Percent | -0.07168295 |
| Type Disp | Equity |
| Volume | 1,535,819 |
| Website | https://www.arcutis.com |
| Zip | 91,361 |